Skip to content

Pharminent

cropped-ChatGPT-Image-May-28-2026-10_46_23-PM.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Other
  • ASCO26: Symptom-tracking app helps advanced cancer patients
  • Other

ASCO26: Symptom-tracking app helps advanced cancer patients

Pharmaphorum

An app used to support people living with advanced cancer has helped them maintain quality of life, and also kept them out of hospital.

Oncology

Read full story

pharminent June 2, 2026 (Last updated: June 4, 2026)

Pharmaphorum

An app used to support people living with advanced cancer has helped them maintain quality of life, and also kept them out of hospital.

Oncology

Read full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: Servier to acquire Edgewise’s muscular dystrophy business for $2.65bn
Next: ASCO ’26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer

Related Stories

  • Other

ASCO ’26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer

pharminent June 2, 2026
  • Other

All eyes on Revolution, bispecific antibodies and more at ASCO26

pharminent May 26, 2026
  • Other

225: An Interview With Craig Martin, Founder and CEO of the Orphan Therapeutics Accelerator

pharminent May 18, 2026

You May Have Missed

  • Commercial

Lilly and Novo face off at ADA 2026 as others seek to compete in obesity

pharminent June 5, 2026
  • Market Access

Medicare Advantage in 2026: Enrollment Update and Key Trends

pharminent June 5, 2026
  • Policy / Pricing

The next FDA commissioner must be a champion for gene therapies

pharminent June 5, 2026
  • Clinical Data

Otsuka energizes IgA neuropathy space with new Phase 3 Voyxact data

pharminent June 5, 2026
Copyright © 2026 All rights reserved. | ReviewNews by AF themes.